Dashboard
Manage Tickers

BMRN


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

scotiabank-maintains-sector-perform-on-biomarin-pharmaceutical-lowers-price-target-to-78
Scotiabank Maintains Sector Perform on Bio...
09/17/2024 15:25:36

Scotiabank analyst George Farmer maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price ...

truist-securities-maintains-buy-on-biomarin-pharmaceutical-lowers-price-target-to-90
Truist Securities Maintains Buy on Biomari...
09/17/2024 14:39:24

Truist Securities analyst Joon Lee maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target fr...

wells-fargo-maintains-overweight-on-biomarin-pharmaceutical-lowers-price-target-to-90
Wells Fargo Maintains Overweight on Biomar...
09/17/2024 14:10:52

Wells Fargo analyst Mohit Bansal maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and lowers the price targ...

rbc-capital-maintains-sector-perform-on-biomarin-pharmaceutical-lowers-price-target-to-85
RBC Capital Maintains Sector Perform on Bi...
09/17/2024 14:01:30

RBC Capital analyst Luca Issi maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and lowers the price tar...

ge-vernova-to-rally-over-30-here-are-10-top-analyst-forecasts-for-tuesday
GE Vernova To Rally Over 30%? Here Are 10 ...
09/17/2024 13:00:39

b-of-a-securities-maintains-buy-on-biomarin-pharmaceutical-lowers-price-target-to-115
B of A Securities Maintains Buy on Biomari...
09/17/2024 12:21:15

B of A Securities analyst Geoff Meacham maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price targ...

stifel-maintains-buy-on-biomarin-pharmaceutical-lowers-price-target-to-87
Stifel Maintains Buy on Biomarin Pharmaceu...
09/17/2024 12:03:42

Stifel analyst Paul Matteis maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price target from $115...

bernstein-maintains-outperform-on-biomarin-pharmaceutical-lowers-price-target-to-90
Bernstein Maintains Outperform on Biomarin...
09/17/2024 11:54:01

Bernstein analyst William Pickering maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Outperform and lowers the price t...

despite-being-first-mover-biomarins-voxzogo-for-dwarfism-to-face-pressure-from-ascendis-candidate-in-near-term
Despite Being First Mover, BioMarin's Voxz...
09/16/2024 19:12:28

BioMarin stock dips in response to TransCon CNP data, as analysts note TransCon CNP could challenge BioMarin's Voxzogo by l...

canaccord-genuity-maintains-hold-on-biomarin-pharmaceutical-maintains-93-price-target
Canaccord Genuity Maintains Hold on Biomar...
09/13/2024 18:08:20

Canaccord Genuity analyst Whitney Ijem maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Hold and maintains $93 price t...

bmrn---analyzing-biomarin-pharmaceuticals-short-interest
(BMRN) - Analyzing Biomarin Pharmaceutical...
09/10/2024 14:15:21

cantor-fitzgerald-reiterates-overweight-on-biomarin-pharmaceutical-maintains-110-price-target
Cantor Fitzgerald Reiterates Overweight on...
09/09/2024 15:32:45

Cantor Fitzgerald analyst Olivia Brayer reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and maintains $11...

fda-battles-backlog-of-drug-factory-inspections-since-covid-19
FDA Battles Backlog of Drug Factory Inspec...
09/06/2024 15:52:51

FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked.

jp-morgan-maintains-overweight-on-biomarin-pharmaceutical-raises-price-target-to-120
JP Morgan Maintains Overweight on Biomarin...
09/05/2024 16:05:09

JP Morgan analyst Jessica Fye maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the price target ...

rbc-capital-reiterates-sector-perform-on-biomarin-pharmaceutical-maintains-100-price-target
RBC Capital Reiterates Sector Perform on B...
09/05/2024 15:56:19

RBC Capital analyst Luca Issi reiterates Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and maintains $100 pric...

scotiabank-maintains-sector-perform-on-biomarin-pharmaceutical-raises-price-target-to-95
Scotiabank Maintains Sector Perform on Bio...
09/05/2024 15:14:12

Scotiabank analyst George Farmer maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and raises the price ...

biomarin-restructures-outlines-roadmap-to-4b-revenues-by-2027
BioMarin Restructures, Outlines Roadmap To...
09/05/2024 13:51:16

BioMarin aims for $4 billion revenue by 2027, focusing on gene therapy and enzyme treatments, with a robust pipeline set to enh...

piper-sandler-maintains-overweight-on-biomarin-pharmaceutical-raises-price-target-to-122
Piper Sandler Maintains Overweight on Biom...
09/05/2024 13:45:53

Piper Sandler analyst Christopher Raymond maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Overweight and raises the p...

deep-dive-into-biomarin-pharmaceutical-stock-analyst-perspectives-14-ratings
Deep Dive Into Biomarin Pharmaceutical Sto...
09/05/2024 13:00:53

truist-securities-maintains-buy-on-biomarin-pharmaceutical-lowers-price-target-to-118
Truist Securities Maintains Buy on Biomari...
09/05/2024 12:12:54

Truist Securities analyst Robyn Karnauskas maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Buy and lowers the price t...

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION